Summary

Artificial Intelligence (AI) in Medical Diagnostics Market By Diseases (Oncology, Cardiovascular diseases, Neurological Disorders, Respiratory Diseases, Diabetes, and Infectious Diseases And By Application (Imaging Diagnostics, Genomic Diagnostics, Laboratory Diagnostics, Preventive Diagnostics, and Clinical Decision Support), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025?2035
Artificial Intelligence (AI) in Medical Diagnostics market accounted for USD 1.42 billion in 2024 and is expected to reach USD 22.6 Billion by 2035, growing at a CAGR of around 28.6% between 2025 and 2035. AI in medical diagnosis is an evolving market with rapid changes due to advancements in technology and demand for faster and more accurate diagnostic tools. The incorporation of AI in medical imaging and pathology has increased the efficiency of the diagnostic process to allow clinicians to make the right decisions in less time. Hospitals and healthcare providers are implementing AI tools to reduce diagnostic errors and drive efficiency in workflow processes. The increased digitization of healthcare, with the need for precision medicine, has its share of influence on the market. The growth of the market, on the contrary, is also subject to regulatory and ethical considerations. Stakeholders are now seeking to strike the right balance between innovation on one hand and patient safety and data privacy on the other. All these dynamics put together determine the trajectory of market development.
Revolution in Imaging Technologies
The rapid evolution of imaging technologies, such as MRI, CT, and PET scan investigations, with combinations of AI algorithms, was instrumental in enhancing the diagnostic accuracy of medical imaging. AI assists in faster and more accurate interpretations of complex imaging data compared to the traditionally employed methods. This is no longer supportive of early disease detection alone; it also provides avenues for treatment planning. The challenge against human error and enhancing workflow has become critical for hospitals adopting AI. These advances alleviate some of the burden off radiologists' shoulders in scenarios demanding rapid outcomes. Furthermore, an AI's prowess to spot patterns invisible to the naked human eye makes way for accurate diagnoses. As these technologies improve accessibility, their integration with AI will only deepen.
Data Privacy and Security Concerns
One of the major issues in the use of medical diagnostics is that patient-related data is often sensitive and should be protected by rigid regulations, with non-compliance causing ominous legal and ethical consequences. AI systems require huge volumes of data for training and subsidiary use, with queries cropping up as regards safe storage, immigration, and application of this data in the long run. Patients, for example, will be reluctant to change their preferences until people in the health industry share the same fears as they do about the misuse of patient data or unauthorized access. In particular, the region has stringent laws about the privacy of the data. Therefore, the actual complexity is further complicated by complying with the regulations set by HIPAA and GDPR. In summary, therefore, data protection is a key hurdle.
Inclusion within Remote Diagnostics and Telemedicine
Telemedicine, with its popularization, creates new avenues for the role of AI in remote diagnosis. AI can interpret real-time patient information to further aid remote physicians without needing specialized physical consultation. This becomes significant in geography-limited areas where the provision of specialist care is unavailable. Those AI-powered platforms can take care of preliminary evaluations, mark inconsistencies, and further suggest the following steps. This interface between AI and telehealth can perhaps deal with different chronic conditions and their management while streamlining the first-line patient triage. Moreover, it can provide services all the time and raise the response speed to respond to emergency cases. The convergence shall make way for reasonable, cheaper, and more affordable services in healthcare.
Segment Analysis
The categorization in the AI sector ensures that individual questions attack unique diseases and clinical problems. Cancer diagnosis leads to combining AI advancement: they help in detecting tumor masses early in medical images and pathology sections with an extremely high level of accuracy. Neurological pathologies, like Alzheimer's and Parkinson's, similarly benefit from AI analysis of brain images, predicting disease progression. Heart diseases are, in turn, alternatively considered: AI helps to generate and interpret ECGs, echocardiograms, and other cardiac diagnostic information. Thus, AI has a significant advantage for improving diagnostic quality, decreasing errors that could be due to human factors, and facilitating the most efficacious interventions among several specialties.
In this regard, we find the applications of AI that go along with various steps of diagnostic processes. In radiology, AI helps greatly in taking images and indicating any anomalies for improved view and immediate generation of reports. As well are AI uses in pathology for slide scanning, cell classification, and the detection of tumors, all speeding up the procedure and keeping consistency. Genomics finds AI particularly interesting, with mutations found between genes that predict future risks of diseases for application in personalized medicine. AI applications are growing into a variety of other areas, including ophthalmology, cardiology, and emergency care, where decisions are required right away. Thus, this discrepancy in applications shows the malleability of AI to various domains within healthcare diagnostics.
Regional Analysis
North America again raises its head as a highly significant region for the use of AI in medical diagnostics, mainly driven by the region's healthcare structure and a robust R&D ecosystem. It has kept feeding on the presence of large technology companies and their AI innovation incubators. Hospitals and diagnostic labs in the U.S. and Canada have pioneered the adoption of AI technologies for improving clinical outcomes with reduced costs. The regulations and guidelines of these bodies have started to become more explicit on AI tools. There are also many public-private partnerships geared towards this cause of strengthening innovative applications in AI and healthcare. Education and training programs will contribute toward developing a skilled workforce. The amalgamation of all these factors renders a fertile ground for growth for this region.
Competitive Landscape
The competitive landscape of AI in the medical diagnostics market is characterized by a mix of established tech companies, specialized healthcare AI firms, and innovative startups. The key players have indeed occupied the major part of their portfolios through collaborative efforts, acquisitions, and innovative product offerings. However, most have developed into fast, lean, niche-specific startups, finding solutions to specific yet huge diagnostic problems. Their competition is not only based on their end product, technology capability, but also on user-friendliness as well as interoperability with existing systems of collective health. Partnerships with hospitals and research institutions help justify, in real-world environments, AI tools in practice. Intellectual property and proprietary algorithms provide competitive edges to market leaders. Continuous updates and regulatory compliance shall serve as the pillar toward which competition builds itself. The entry barriers are high, and innovation takes place at a very fast pace; hence, the competition is perennially intense yet dynamic.
Report Coverage:
By Application
- Imaging Diagnostics
- Genomic Diagnostics
- Laboratory Diagnostics
- Preventive Diagnostics
- Clinical Decision Support
By Disease
- Oncology
- Cardiovascular diseases
- Neurological Disorders
- Respiratory Diseases
- Diabetes
- Infectious Diseases
- Others

ページTOPに戻る

Table of Contents

Table of Contents
1. Methodology & Report Coverage
1.1. Definition & Objective
1.2. Market Evaluation & forecast parameter
1.3. Research Methodology
1.4. Data Validation Sources
1.4.1. Secondary Research
1.4.2. Primary Research
2. Market Overview
3. Global AI in Medical Diagnostics Market: Market Dynamics
3.1. Executive Summary
3.2. Market Driving Factors
3.2.1. Growing demand for accurate and early disease diagnosis through AI technologies.
3.2.2. Investment in AI healthcare startups and research for innovative solutions fosters growth.
3.2.3. The rising prevalence of chronic diseases necessitates advanced diagnostic tools.
3.3. Key industry pitfalls & challenges
3.3.1. High initial costs of AI implementation and integration into healthcare systems.
3.3.2. Concerns over data privacy and security for sensitive patient health information.
3.3.3. Regulatory uncertainties and lengthy approval processes for AI diagnostic solutions.
3.4. Market Opportunities
3.4.1. Partnerships between AI startups and healthcare providers can develop innovative solutions.
3.4.2. integration of AI with imaging technologies for faster, more accurate diagnoses.
3.4.3. AI adoption in underserved and rural areas to enhance access to diagnostic care.
3.5. Porter’s Five Forces Analysis
3.6. PESTLE Analysis
3.7. Regulatory landscape
3.8. Pipeline Analysis
3.9. ESG Scenario
3.10. Competitive landscape
3.10.1. Company Market Share
3.10.2. Market Positioning
3.10.3. Strategy framework
3.10.4. Recent Acquisitions & Mergers
4. AI in Medical Diagnostics Market, Application Type Segment Analysis
4.1. Overview Dynamics
4.1.1. Market Revenue Share, By Application Type, 2025 & 2035
4.1.2. Key Market Trends, Growth Factors, & Opportunities
4.2. Imaging Diagnostics
4.2.1. Market Size and Forecast, By 2025-2035 (USD Billion)
4.3. Genomic Diagnostics
4.3.1. Market Size and Forecast, By 2025-2035 (USD Billion)
4.4. Laboratory Diagnostics
4.4.1. Market Size and Forecast, By 2025-2035 (USD Billion)
4.5. Preventive Diagnostic
4.5.1. Market Size and Forecast, By 2025-2035 (USD Billion)
4.6. Clinical Decision Support
4.6.1. Market Size and Forecast, By 2025-2035 (USD Billion)
5. AI in Medical Diagnostics Market, Diseases Segment Analysis
5.1. Overview
5.1.1. Market Revenue Share, By Diseases, 2025 & 2035
5.1.2. Key Market Trends, Growth Factors, & Opportunities
5.2. Oncology
5.2.1. Market Size and Forecast, By 2025-2035 (USD Billion)
5.3. Cardiovascular diseases
5.3.1. Market Size and Forecast, By 2025-2035(USD Billion)
5.4. Neurological Disorders
5.4.1. Market Size and Forecast, By 2025-2035 (USD Billion)
5.5. Respiratory Diseases
5.5.1. Market Size and Forecast, By 2025-2035 (USD Billion)
5.6. Diabetes
5.6.1. Market Size and Forecast, By 2025-2035 (USD Billion)
5.7. Infectious Diseases
5.7.1. Market Size and Forecast, By 2025-2035 (USD Billion)
5.8. Others
5.8.1. Market Size and Forecast, By 2025-2035 (USD Billion)
6. AI in Medical Diagnostics Market, Region Segment Analysis
6.1. Overview
6.1.1. Global Market Revenue Share, By Region, 2025 & 2035
6.1.2. Global Market Revenue, By Region, 2025-2035 (USD Billion)
6.2. North America
6.2.1. North America Market Revenue, By Country, 2025-2035 (USD Billion)
6.2.2. North America Market Revenue, By Application Type, 2025-2035
6.2.3. North America Market Revenue, By Diseases, 2025-2035
6.2.4. The U.S.
6.2.4.1. U.S. Market Revenue, By Application Type, 2025-2035
6.2.4.2. U.S. Market Revenue, By Diseases, 2025-2035
6.2.5. Canada
6.2.5.1. Canada Market Revenue, By Application Type, 2025-2035
6.2.5.2. Canada Market Revenue, By Diseases, 2025-2035
6.3. Europe
6.3.1. Europe Market Revenue, By Country, 2025-2035 (USD Billion)
6.3.2. Europe Market Revenue, By Application Type, 2025-2035
6.3.3. Europe Market Revenue, By Diseases, 2025-2035
6.3.4. Germany
6.3.4.1. Germany Market Revenue, By Application Type, 2025-2035
6.3.4.2. Germany Market Revenue, By Diseases, 2025-2035
6.3.5. France
6.3.5.1. France Market Revenue, By Application Type, 2025-2035
6.3.5.2. France Market Revenue, By Diseases, 2025-2035
6.3.6. U.K.
6.3.6.1. U.K. Market Revenue, By Application Type, 2025-2035
6.3.6.2. U.K. Market Revenue, By Diseases, 2025-2035
6.3.7. Italy
6.3.7.1. Italy Market Revenue, By Application Type, 2025-2035
6.3.7.2. Italy Market Revenue, By Diseases, 2025-2035
6.3.8. Spain
6.3.8.1. Spain Market Revenue, By Application Type, 2025-2035
6.3.8.2. Spain Market Revenue, By Diseases, 2025-2035
6.3.9. Rest of Europe
6.3.9.1. Rest of Europe Market Revenue, By Application Type, 2025-2035
6.3.9.2. Rest of Europe Market Revenue, By Diseases, 2025-2035
6.4. Asia Pacific
6.4.1. Asia Pacific Market Revenue, By Country, 2025-2035 (USD Billion)
6.4.2. Asia Pacific Market Revenue, By Application Type, 2025-2035
6.4.3. Asia Pacific Market Revenue, By Diseases, 2025-2035
6.4.4. China
6.4.4.1. China Market Revenue, By Application Type, 2025-2035
6.4.4.2. China Market Revenue, By Diseases, 2025-2035
6.4.5. Japan
6.4.5.1. Japan Market Revenue, By Application Type, 2025-2035
6.4.5.2. Japan Market Revenue, By Diseases, 2025-2035
6.4.6. India
6.4.6.1. India Market Revenue, By Application Type, 2025 – 2035
6.4.6.2. India Market Revenue, By Diseases, 2025-2035
6.4.7. Australia
6.4.7.1. Australia Market Revenue, By Application Type, 2025 – 2035
6.4.7.2. Australia Market Revenue, By Diseases, 2025-2035
6.4.8. South Korea
6.4.8.1. South Korea Market Revenue, By Application Type, 2025-2035
6.4.8.2. South Korea Market Revenue, By Diseases, 2025-2035
6.4.9. Singapore
6.4.9.1. Singapore Market Revenue, By Application Type, 2025-2035
6.4.9.2. Singapore Market Revenue, By Diseases, 2025-2035
6.4.10. Rest of Asia Pacific
6.4.10.1. Rest of Asia Pacific Market Revenue, By Application Type, 2025-2035
6.4.10.2. Rest of Asia Pacific Market Revenue, By Diseases, 2025-2035
6.5. Latin America
6.5.1. Latin America Market Revenue, By Country, 2025-2035 (USD Billion)
6.5.2. Latin America Market Revenue, By Application Type, 2025-2035
6.5.3. Latin America Market Revenue, By Diseases, 2025-2035
6.5.4. Brazil
6.5.4.1. Brazil Market Revenue, By Application Type, 2025-2035
6.5.4.2. Brazil Market Revenue, By Diseases, 2025-2035
6.5.5. Argentina
6.5.5.1. Argentina Market Revenue, By Application Type, 2025-2035
6.5.5.2. Argentina Market Revenue, By Diseases, 2025-2035
6.5.6. Mexico
6.5.6.1. Mexico Market Revenue, By Application Type, 2025-2035
6.5.6.2. Mexico Market Revenue, By Diseases, 2025-2035
6.5.7. Rest of Latin America
6.5.7.1. Rest of Latin America Market Revenue, By Application Type, 2025-2035
6.5.7.2. Rest of Latin America Market Revenue, By Diseases, 2025-2035
6.6. MEA
6.6.1. MEA Market Revenue, By Country, 2025-2035 (USD Billion)
6.6.2. MEA Market Revenue, By Application Type, 2025-2035
6.6.3. MEA Market Revenue, By Diseases, 2025-2035
6.6.4. GCC Countries
6.6.4.1. GCC Countries Market Revenue, By Application Type, 2025-2035
6.6.4.2. GCC Countries Market Revenue, By Diseases, 2025-2035
6.6.5. South Africa
6.6.5.1. South Africa Market Revenue, By Application Type, 2025-2035
6.6.5.2. South Africa Market Revenue, By Diseases, 2025-2035
6.6.6. Rest of Middle-East Africa
6.6.6.1. Rest of Middle-East Africa Market Revenue, By Application Type, 2025-2035
6.6.6.2. Rest of Middle-East Africa Market Revenue, By Diseases, 2025-2035
7. Company Profile
7.1. NVIDIA Corporation
7.1.1. Business Overview
7.1.2. Financial Performance
7.1.3. Component/Service Offerings
7.1.4. Strategies & recent developments
7.1.5. SWOT Analysis
7.2. Siemens Healthineers
7.2.1. Business Overview
7.2.2. Financial Performance
7.2.3. Component/Service Offerings
7.2.4. Strategies & recent developments
7.2.5. SWOT Analysis
7.3. GE HealthCare
7.3.1. Business Overview
7.3.2. Financial Performance
7.3.3. Component/Service Offerings
7.3.4. Strategies & recent developments
7.3.5. SWOT Analysis
7.4. Google
7.4.1. Business Overview
7.4.2. Financial Performance
7.4.3. Component/Service Offerings
7.4.4. Strategies & recent developments
7.4.5. SWOT Analysis
7.5. Microsoft
7.5.1. Business Overview
7.5.2. Financial Performance
7.5.3. Component/Service Offerings
7.5.4. Strategies & recent developments
7.5.5. SWOT Analysis
7.6. Intel Corporation
7.6.1. Business Overview
7.6.2. Financial Performance
7.6.3. Component/Service Offerings
7.6.4. Strategies & recent developments
7.6.5. SWOT Analysis
7.7. IBM Watson Health
7.7.1. Business Overview
7.7.2. Financial Performance
7.7.3. Component/Service Offerings
7.7.4. Strategies & recent developments
7.7.5. SWOT Analysis
7.8. Philips Healthcare
7.8.1. Business Overview
7.8.2. Financial Performance
7.8.3. Component/Service Offerings
7.8.4. Strategies & recent developments
7.8.5. SWOT Analysis
7.9. Digital Diagnostics Inc.
7.9.1. Business Overview
7.9.2. Financial Performance
7.9.3. Component/Service Offerings
7.9.4. Strategies & recent developments
7.9.5. SWOT Analysis
7.10. HeartFlow, Inc.
7.10.1. Business Overview
7.10.2. Financial Performance
7.10.3. Component/Service Offerings
7.10.4. Strategies & recent developments
7.10.5. SWOT Analysis
7.11. Butterfly Network, Inc
7.11.1. Business Overview
7.11.2. Financial Performance
7.11.3. Component/Service Offerings
7.11.4. Strategies & recent developments
7.11.5. SWOT Analysis.
7.12. Zebra Medical Vision
7.12.1. Business Overview
7.12.2. Financial Performance
7.12.3. Component/Service Offerings
7.12.4. Strategies & recent developments
7.12.5. SWOT Analysis
7.13. Aidence
7.13.1. Business Overview
7.13.2. Financial Performance
7.13.3. Component/Service Offerings
7.13.4. Strategies & recent developments
7.13.5. SWOT Analysis
7.14. Enlitic, Inc.
7.14.1. Business Overview
7.14.2. Financial Performance
7.14.3. Component/Service Offerings
7.14.4. Strategies & recent developments
7.14.5. SWOT Analysis
7.15. Icometrix
7.15.1. Business Overview
7.15.2. Financial Performance
7.15.3. Component/Service Offerings
7.15.4. Strategies & recent developments
7.15.5. SWOT Analysis

ページTOPに戻る

List of Tables/Graphs

Tables
TABLE 1. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY DISEASE, 2025-2035 (USD BILLION)
TABLE 2. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE FOR ACTIVATED CARBON, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE FOR CARBON DERIVATIVES, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE FOR METAL OXIDES, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE FOR CONDUCTIVE POLYMERS, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 6. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE FOR CONSUMER ELECTRONICS, 2025-2035 (USD BILLION)
TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE FOR INDUSTRIAL, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE FOR TRANSPORTATION, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 12. NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2025-2035 (USD BILLION)
TABLE 13. NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY DISEASE, 2025-2035 (USD BILLION)
TABLE 14. NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 15. U.S ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY DISEASE, 2025-2035 (USD BILLION)
TABLE 16. U.S ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 17. CANADA ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY DISEASE, 2025-2035 (USD BILLION)
TABLE 18. CANADA ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 19. EUROPE ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2025-2035 (USD BILLION)
TABLE 20. EUROPE ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY DISEASE, 2025-2035 (USD BILLION)
TABLE 21. EUROPE ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, END-USERS, 2025-2035 (USD BILLION)
TABLE 22. GERMANY ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY DISEASE, 2025-2035 (USD BILLION)
TABLE 23. GERMANY ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 24. U.K ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY DISEASE, 2025-2035 (USD BILLION)
TABLE 25. U.K ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 26. FRANCE ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY DISEASE, 2025-2035 (USD BILLION)
TABLE 27. FRANCE ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 28. ITALY ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY DISEASE, 2025-2035 (USD BILLION)
TABLE 29. ITALY ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 30. SPAIN ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY DISEASE, 2025-2035 (USD BILLION)
TABLE 31. SPAIN ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 32. ROE ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY DISEASE, 2025-2035 (USD BILLION)
TABLE 33. ROE ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 34. ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2025-2035 (USD BILLION)
TABLE 35. ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY DISEASE, 2025-2035 (USD BILLION)
TABLE 36. ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 37. CHINA ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY DISEASE, 2025-2035 (USD BILLION)
TABLE 38. CHINA ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 39. INDIA ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY DISEASE, 2025-2035 (USD BILLION)
TABLE 40. INDIA ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 41. JAPAN ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY DISEASE, 2025-2035 (USD BILLION)
TABLE 42. JAPAN ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 43. REST OF APAC ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY DISEASE, 2025-2035 (USD BILLION)
TABLE 44. REST OF APAC ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 45. REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY DISEASE, 2025-2035 (USD BILLION)
TABLE 46. REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN MEDICAL DIAGNOSTICS MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 47. CABOT(NORIT): FINANCIALS
TABLE 48. CABOT(NORIT): PRODUCTS & SERVICES
TABLE 49. CABOT(NORIT): RECENT DEVELOPMENTS
TABLE 50. KURARY CO. LTD: FINANCIALS
TABLE 51. KURARY CO. LTD: PRODUCTS & SERVICES
TABLE 52. KURARY CO. LTD: RECENT DEVELOPMENTS
TABLE 53. BAYER MATERIALSCIENCE AG: FINANCIALS
TABLE 54. BAYER MATERIALSCIENCE AG: PRODUCTS & SERVICES
TABLE 55. BAYER MATERIALSCIENCE AG: RECENT DEVELOPMENTS
TABLE 56. CALGON CARBON CORPORATION: FINANCIALS
TABLE 57. CALGON CARBON CORPORATION: PRODUCTS & SERVICES
TABLE 58. CALGON CARBON CORPORATION: RECENT DEVELOPMENTS
TABLE 59. CARBON NT&F: FINANCIALS
TABLE 60. CARBON NT&F: PRODUCTS & SERVICES
TABLE 61. CARBON NT&F: RECENT DEVELOPMENTS
TABLE 62. SHENZHEN NTP: FINANCIALS
TABLE 63. SHENZHEN NTP: PRODUCTS & SERVICES
TABLE 64. SHENZHEN NTP: RECENT DEVELOPMENTS
TABLE 65. CECA SA: FINANCIALS
TABLE 66. CECA SA: PRODUCTS & SERVICES
TABLE 67. CECA SA: RECENT DEVELOPMENTS
TABLE 68. CNANO TECHNOLOGY: FINANCIALS
TABLE 69. CNANO TECHNOLOGY: PRODUCTS & SERVICES
TABLE 70. CNANO TECHNOLOGY: RECENT DEVELOPMENTS
TABLE 71. DONAU CHEMIE GROUP: FINANCIALS
TABLE 72. DONAU CHEMIE GROUP: PRODUCTS & SERVICES
TABLE 73. DONAU CHEMIE GROUP: RECENT DEVELOPMENTS
TABLE 74. SHOWA DENKO: FINANCIALS
TABLE 75. SHOWA DENKO: PRODUCTS & SERVICES
TABLE 76. SHOWA DENKO: RECENT DEVELOPMENTS